دورية أكاديمية
أعرض في EDS

Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration.

التفاصيل البيبلوغرافية
العنوان: Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration.
المؤلفون: Tedeschi SK; Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Johnson SR; Toronto Western Hospital and University of Toronto, Toronto, Ontario, Canada., Boumpas D; University of Crete, Heraklion, Greece., Daikh D; University of California at San Francisco and VA Medical Center, San Francisco., Dörner T; Charite University Hospitals, Berlin, Germany., Jayne D; University of Cambridge, Cambridge, UK., Kamen D; Medical University of South Carolina, Charleston., Lerstrøm K; LUPUS EUROPE, Farum, Denmark., Mosca M; University of Pisa, Pisa, Italy., Ramsey-Goldman R; Northwestern University, Chicago, Illinois., Sinnette C; Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Wofsy D; University of California at San Francisco., Smolen JS; Medical University of Vienna, Vienna Austria., Naden RP; McMaster University, Hamilton, Ontario, Canada., Aringer M; University Medical Center Carl Gustav Carus, Technical University of Dresden, Dresden, Germany., Costenbader KH; Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
المصدر: Arthritis care & research [Arthritis Care Res (Hoboken)] 2018 Apr; Vol. 70 (4), pp. 571-581. Date of Electronic Publication: 2018 Feb 22.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
اللغة: English
بيانات الدورية: Publisher: John Wiley & Sons Country of Publication: United States NLM ID: 101518086 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2151-4658 (Electronic) Linking ISSN: 2151464X NLM ISO Abbreviation: Arthritis Care Res (Hoboken) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Hoboken, NJ : John Wiley & Sons
مواضيع طبية MeSH: Lupus Erythematosus, Systemic*/classification , Lupus Erythematosus, Systemic*/diagnosis , Lupus Erythematosus, Systemic*/immunology , Lupus Erythematosus, Systemic*/therapy , Terminology as Topic*, Humans ; Antibodies, Antinuclear/blood ; Antibodies, Antinuclear/immunology ; Biomarkers/blood ; Complement System Proteins/immunology ; Consensus ; Delphi Technique ; Europe ; International Cooperation ; Predictive Value of Tests ; Prognosis ; Reproducibility of Results ; Severity of Illness Index ; United States
مستخلص: Objective: To define candidate criteria within multiphase development of systemic lupus erythematosus (SLE) classification criteria, jointly supported by the American College of Rheumatology and the European League Against Rheumatism. Prior steps included item generation and reduction by Delphi exercise, further narrowed to 21 items in a nominal group technique exercise. Our objectives were to apply an evidence-based approach to the 21 candidate criteria, and to develop hierarchical organization of criteria within domains.
Methods: A literature review identified the sensitivity and specificity of the 21 candidate criteria. Data on the performance of antinuclear antibody (ANA) as an entry criterion and operating characteristics of the candidate criteria in early SLE patients were evaluated. Candidate criteria were hierarchically organized into clinical and immunologic domains, and definitions were refined in an iterative process.
Results: Based on the data, consensus was reached to use a positive ANA of ≥1:80 titer (HEp-2 cells immunofluorescence) as an entry criterion and to have 7 clinical and 3 immunologic domains, with hierarchical organization of criteria within domains. Definitions of the candidate criteria were specified.
Conclusion: Using a data-driven process, consensus was reached on new, refined criteria definitions and organization based on operating characteristics. This work will be followed by a multicriteria decision analysis exercise to weight criteria and to identify a threshold score for classification on a continuous probability scale.
(© 2017, American College of Rheumatology.)
References: Arthritis Care Res (Hoboken). 2018 Oct;70(10):1488-1494. (PMID: 29287313)
Arthritis Rheum. 2006 Feb;54(2):421-32. (PMID: 16453282)
J Autoimmun. 2016 Nov;74:182-193. (PMID: 27338520)
J Am Acad Dermatol. 2017 Aug;77(2):261-267. (PMID: 28606712)
Arthritis Rheum. 2012 Aug;64(8):2677-86. (PMID: 22553077)
Kidney Int. 2004 Feb;65(2):521-30. (PMID: 14717922)
J Rheumatol. 2004 Nov;31(11):2156-62. (PMID: 15517627)
Arthritis Rheum. 1997 Sep;40(9):1725. (PMID: 9324032)
Arthritis Rheum. 2010 Sep;62(9):2582-91. (PMID: 20872596)
Arthritis Rheum. 2007 Jan;56(1):265-73. (PMID: 17195230)
Arthritis Rheumatol. 2015 May;67(5):1305-13. (PMID: 25605554)
Lupus. 2016 Jul;25(8):805-11. (PMID: 27252256)
Lupus Sci Med. 2014 Oct 01;1(1):e000056. (PMID: 25396070)
Baillieres Clin Rheumatol. 1995 May;9(2):253-66. (PMID: 7656339)
J Clin Epidemiol. 2014 Jun;67(6):706-14. (PMID: 24721558)
Arthritis Care Res (Hoboken). 2012 Mar;64(3):358-67. (PMID: 22052658)
Arthritis Rheum. 2007 Oct 15;57(7):1119-33. (PMID: 17907227)
Arthritis Rheumatol. 2017 Mar;69(3):630-642. (PMID: 27863174)
J Rheumatol. 2014 Aug;41(8):1720-1. (PMID: 25086139)
J Am Acad Dermatol. 1981 Apr;4(4):471-5. (PMID: 7229150)
J Thromb Haemost. 2006 Feb;4(2):295-306. (PMID: 16420554)
Arthritis Rheum. 1999 Apr;42(4):599-608. (PMID: 10211873)
Arch Intern Med. 1992 Jan;152(1):21-2. (PMID: 1728921)
Medicine (Baltimore). 1999 May;78(3):167-75. (PMID: 10352648)
Clin Rheumatol. 2015 Mar;34(3):471-7. (PMID: 25597615)
Arthritis Rheum. 2013 Nov;65(11):2737-47. (PMID: 24122180)
Arthritis Rheum. 2006 Jun 15;55(3):348-52. (PMID: 16739201)
Arthritis Rheumatol. 2015 Oct;67(10):2557-68. (PMID: 26352873)
Arthritis Rheum. 1982 Nov;25(11):1271-7. (PMID: 7138600)
Arthritis Care Res (Hoboken). 2017 Dec;69(12):1780-1788. (PMID: 28118528)
Arthritis Rheum. 2007 Oct 15;57(7):1112-5. (PMID: 17907226)
Ann Rheum Dis. 2010 Mar;69(3):529-35. (PMID: 19359262)
Arthritis Care Res (Hoboken). 2018 Mar;70(3):428-438. (PMID: 28544593)
معلومات مُعتمدة: K24 AR066109 United States AR NIAMS NIH HHS; L30 AR070514 United States AR NIAMS NIH HHS
المشرفين على المادة: 0 (Antibodies, Antinuclear)
0 (Biomarkers)
9007-36-7 (Complement System Proteins)
تواريخ الأحداث: Date Created: 20170711 Date Completed: 20190107 Latest Revision: 20240402
رمز التحديث: 20240403
مُعرف محوري في PubMed: PMC5996759
DOI: 10.1002/acr.23317
PMID: 28692774
قاعدة البيانات: MEDLINE
الوصف
تدمد:2151-4658
DOI:10.1002/acr.23317